ESCC
Showing 1 - 25 of 250
Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- AK104, nab-paclitaxel, carboplatin
-
Anyang, Henan, China
- +1 more
Jun 1, 2023
Esophagus Cancer Trial in Xiamen (Tislelizumab, Paclitaxel-albumin, Carboplatin)
Recruiting
- Esophagus Cancer
- Tislelizumab
- +2 more
-
Xiamen, Fujian, ChinaShanghaiZhongshan
Apr 8, 2023
Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- PD-1 Inhibitors
-
Zhengzhou, Henan, ChinaFeng Wang
Oct 9, 2023
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Beijing (Esophagectomy)
Active, not recruiting
- Esophageal Squamous Cell Carcinoma
- Oligometastatic Disease
- Esophagectomy
-
Beijing, China
- +1 more
Jul 11, 2023
Advanced Esophageal Squamous Cell Carcinoma Trial in Beijing, Xiamen, Xinxiang (Afatinib, Irinotecan)
Recruiting
- Advanced Esophageal Squamous Cell Carcinoma
-
Beijing, China
- +2 more
Apr 6, 2023
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Locally Advanced Carcinoma
- Tislelizumab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Jul 19, 2022
Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Tislelizumab
- +3 more
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Institute & Hospital
May 24, 2022
Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Beijing, Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 13, 2022
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (Radiotherapy, Toripalimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Radiotherapy
- Toripalimab
- (no location specified)
Mar 17, 2023
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC
Completed
- Neoplasm, Esophagus
- Neoplasm, Squamous Cell
- nCRT
- (no location specified)
Apr 20, 2023
Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai (Radiotherapy)
Recruiting
- Metastatic Esophageal Squamous Cell Carcinoma
- Radiotherapy
-
Shanghai, ChinaFudan University Shanghai cancer center
Feb 27, 2023
Index of Lymphadenectomy for Thoracic Escc
Completed
- Esophageal Cancer
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital and Research Institute
Nov 3, 2022
NLR and Its Association With Efficacy of Immunochemotherapy in
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Nov 10, 2023
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)
Not yet recruiting
- Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- SBRT
- Cadonilimab
- (no location specified)
Feb 8, 2023
Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Tiragolumab)
Not yet recruiting
- Locally Advanced Esophageal Squamous Cell Carcinoma
- (no location specified)
Feb 23, 2023
Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- LDRT+CFRT
- +2 more
-
Shanghai, China
- +1 more
Aug 3, 2023
Esophageal Squamous Cell Carcinoma Trial (Combination (S095033 + paclitaxel))
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Combination (S095033 + paclitaxel)
- (no location specified)
Mar 28, 2022
Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)
Not yet recruiting
- Esophageal Squamous Carcinoma
- HER-2 Protein Overexpression
- (no location specified)
Sep 24, 2023
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Oligometastatic Disease
- PD-1 combined with SBRT
-
Guangzhou, Guangdong, ChinaMian Xi
Dec 18, 2022
Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,
Recruiting
- Esophageal Cancer by AJCC V8 Stage
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Feb 12, 2023
Esophageal Cancer Trial in Tianjin (Arm A, Arm B)
Not yet recruiting
- Esophageal Cancer
- Arm A
- Arm B
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Sep 24, 2023
Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Taipei (Nivolumab)
Recruiting
- Locally Advanced Esophageal Squamous Cell Carcinoma
-
Taipei, TaiwanNational Taiwan University Hospital
Nov 22, 2021
Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Cadonilimab combined Anlotinib
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023
Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Consolidation chemotherapy (4 courses)
- Concurrent chemotherapy (2 courses)
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Mar 16, 2023
ctDNA-MRD in Predicting Efficacy of Esophageal Squamous Cell
Not yet recruiting
- Squamous Cell Carcinoma of Esophagus
- (no location specified)
Feb 25, 2023